A study in npj Parkinson’s Disease reports that selectively degrading alpha-synuclein can block aggregation triggered by preformed fibrils (PFFs). Researchers describe a targeted protein degradation strategy designed to reduce the availability of alpha-synuclein species required for misfolding and accumulation. The work’s mechanistic focus is on aggregation biology—one of the central hypotheses in synucleinopathies—and it frames the approach as a way to prevent the protein from forming toxic aggregates rather than merely inhibiting upstream pathways. By showing blockade of PFF-induced aggregation, the findings provide preclinical support for degradation-based therapies in Parkinson’s disease, where multiple modalities are under investigation including antibodies, small molecules, and gene-silencing approaches. For drug developers, degradation carries a distinct translational profile: it can create a more durable reduction in target levels, but it also requires careful assessment of safety, brain penetration, and specificity across synuclein isoforms and related proteins in later studies.